ESSA Pharma to Participate in the 2024 Cantor Global Healthcare Conference
ESSA Pharma Inc. (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on creating innovative therapies for prostate cancer, is thrilled to share that it will participate in the 2024 Cantor Global Healthcare Conference. This conference represents a valuable opportunity for ESSA to showcase its most recent progress in cancer treatments.
Details of the Conference
On September 18, 2024, key executives from ESSA Pharma will take part in a fireside chat. This session will feature David R. Parkinson, the President and CEO, alongside Peter Virsik, the Chief Operating Officer and Executive Vice President, as well as David S. Wood, the Chief Financial Officer. They will discuss the company’s strategic goals and significant research efforts aimed at improving treatments for prostate cancer.
Accessing the Live Webcast
The fireside chat will be accessible through a live webcast, which you can find in the Investors/Events & Presentations section of the ESSA website. After the event, the recorded webcast will be available for 90 days, making it easy for investors and anyone interested to catch up on the company’s latest developments.
About ESSA Pharma Inc.
ESSA Pharma is committed to developing special therapies aimed at treating prostate cancer. The goal is to provide effective and innovative solutions for patients facing this challenge. Those interested can explore the company's website for more detailed insights into its mission and current projects.
Ongoing Commitment to Innovation
ESSA Pharma continuously strives to create innovative solutions tailored for cancer care. Their dedication to prostate cancer treatment addresses the urgent need for effective therapies in a field that impacts countless individuals. The insights shared during the conference will highlight unique strategies that ESSA Pharma has undertaken to improve patient outcomes.
Fostering Relationships with Investors and Collaborators
Attending key conferences like this one emphasizes ESSA's commitment to maintaining transparency and collaboration with investors and stakeholders. It also demonstrates their drive to leverage cutting-edge research to enhance treatment options for prostate cancer. This kind of engagement is essential for building relationships with medical professionals and the scientific community, reinforcing the importance of discussions around health innovations.
Frequently Asked Questions
What will ESSA Pharma present at the conference?
ESSA Pharma will share its latest advancements in developing therapies for prostate cancer during a fireside chat.
Who are the speakers representing ESSA during the chat?
The chat will include David R. Parkinson, Peter Virsik, and David S. Wood as key speakers, who will provide insights into the company's initiatives.
How can I access the webcast of the presentation?
You can access the live webcast through the Investors section of the ESSA Pharma website. It will also be available on-demand for 90 days after the event.
What is the main focus of ESSA Pharma?
ESSA Pharma is dedicated to developing innovative therapies specifically aimed at treating prostate cancer, with the goal of enhancing the lives of affected patients.
Where can I find more information about ESSA Pharma's projects?
For more detailed information, visit ESSA Pharma's official website, where updates on their projects and initiatives are regularly posted.